Luis Borges, CSO will spearhead the Company’s global research group, including teams in London, Zurich and Houston. Luis brings extensive knowledge of cancer immunotherapy from twenty years of experience in the field, including senior positions at Five Prime Therapeutics and Amgen, where he played a senior role in the discovery and development of several blockbuster drugs and therapeutic candidate molecules.
The Company has significantly expanded its pre-clinical pipeline through partnerships with Baylor College of Medicine in the field of chimeric antigen receptors (CARs) and with University College London for engineered T cell receptors (TCRs). Luis will assume responsibility for the Company’s pre-clinical and early product development activities and will join the steering committees managing Cell Medica’s research collaborations.
“Luis has extensive experience working with different technologies to develop drugs which activate and target the human immune system to treat cancer. His proven R&D management expertise will accelerate and de-risk our product generation capabilities.”
“This is a remarkable time for the cellular immunotherapy industry. Cell Medica is well-positioned with advanced and differentiated technologies, which have the potential to make a real difference for cancer patients, and I look forward to joining a senior team which is committed to achieving this objective.”
Dr Luis Borges has extensive experience in the research and development of cancer immunotherapies within successful biotech companies. Luis joins Cell Medica from Five Prime Therapeutics, where he served as Senior Vice President, Research and was instrumental in refocusing the product pipeline on cancer immunotherapy. During his previous twelve years at Amgen, Luis was involved in several successful hematology and oncology drug development programs. Luis began his career at Immunex, an innovative immunology-based biotech company, which was acquired by Amgen. Luis’s scientific and drug development research has included various technologies based on antibodies, and work with different immune cells including T cells, NK cells, and dendritic cells. Dr Borges earned his doctorate in Pathology at the University of Washington, Seattle, WA. His work has been published in a number of peer-reviewed journals.